Volume 3, Issue 13


Cover Image

Cover Figure: Hematoxylin and eosin–stained PtenΔ/ΔStat3βTG mouse at day 20 postinduction, ie, Pten deletion.
See the article Aigner et al.

WASHINGTON, D.C., July 9, 2019 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

Genomic instability has been linked to a number of diseases, including malignancies of the hematopoiesis. Bresnick and Johnson review the role of transcriptional enhancers, with a particular focus on GATA2-based mechanisms, with the goal of dissecting enhancer mechanisms to guide future interventions.


New therapeutic targets for the treatment of patients with acute myeloid leukemia are urgently needed. Erba and colleagues report the initial use of AMG 232, an oral, selective MDM2 inhibitor for the treatment of p53 wild-type cancers. This study demonstrates this agent's efficacy and general tolerability with the target dose identified, setting the stage for larger future studies.


It is well recognized that there are many polymorphisms in the Fc-γ receptor that may impact disease activity and treatment. Schmidt and colleagues explored the impact of these polymorphisms on disease susceptibility, treatment with intravenous immunoglobulin, and long-term outcomes of immune thrombocytopenia patients. They obtained interesting and provocative results.


The use of T cells engineered to express a specific T-cell receptor is an attractive immunotherapeutic concept. NY–ESO-1 has emerged as a target overexpressed on a number of different malignancies, including multiple myeloma. Stadtmauer and colleagues report the outcomes of patients treated with this novel approach in the context of an autologous transplant, demonstrating safety and evidence for efficacy.


Natural killer (NK) cells have innate ability to recognize and kill malignant cells and have been explored as a novel approach to adoptive cell therapy for cancer. Further, the use of haploidentical NK cells from a normal donor has a number of attractive qualities. However, a limitation has been the need for the coadministration of interleukin-2 (IL-2) to enhance NK cell proliferation and survival. Cooley and colleagues at the University of Minnesota reach provocative conclusions using IL-15 instead of IL-2.


Links between the composition of the intestinal microbiome and cancer are becoming increasingly known. Pianko and colleagues explored the relationship between achieving a state of minimal residual disease after treatment for multiple myeloma and the composition of the intestinal microbiome, with stimulating findings.


Featured Visual Abstract

Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes

Megan M. Herr, Sara J. Schonfeld, Graça M. Dores, Eric A. Engels, Margaret A. Tucker, Rochelle E. Curtis and Lindsay M. Morton




Blood Advances is the open-access journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.